Fund moves
2.4%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
XBIO · NASDAQ · Pharmaceutical Preparations
Xenetic Biosciences (XBIO) · oqro.io/stocks/XBIO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.49−0.17 (−10.24%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
No open-market purchase by an insider of Xenetic Biosciences is on record in SEC filings since 2006.
No open-market sale by an insider of Xenetic Biosciences (XBIO) was filed with the SEC in the last 90 days.
No trade in Xenetic Biosciences (XBIO) was disclosed by a member of Congress in the last 12 months.
Xenetic Biosciences's next results are expected on Mar 10, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−40.2% (−$1.00) from Nov 17, 2025 to Nov 16, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $2.49 on Nov 17, 2025 to $1.49 on Nov 16, 2026 (−40.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Framingham, Ma.
Last 12 months
−42.7%
Market value
$3.49M
S&P 500 +10.1% over the same dates. Prices adjusted for splits and dividends.
Short interest: 37K shares sold short (1.6% of shares outstanding), +237.7% vs the previous count, 1.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$725K
−29.4% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $5.81M, at Sep 30, 2026
Net income, last 12 months
−$3.66M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 13, 2026.
Revenue, fiscal 2025
$2.98M
+19.0% vs the year before
Net income, fiscal 2025
−$2.68M
A loss for the year
Shares outstanding
2.34M
As of Nov 6, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last results
Nov 13, 2026
Within the 30 days after it, until Dec 13, 2026
Next results, expected
Mar 10, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Xenetic Biosciences's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Xenetic Biosciences's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.